CANCER BIOMARKERS Russian patent published in 2012 - IPC G01N33/574 G01N33/96 

FIELD: medicine.

SUBSTANCE: what is presented is a diagnostic and monitoring technique for prostate cancer progression involving detection and/or evaluation of a homeodomain-containing transcription EN-2 factor or its urinary fragment, and comparison the amount of said homeodomain-containing transcription factor in a tested urine sample with that found in the reference sample taken from a normal healthy subject wherein increasing the level of homeodomain-containing transcription factor or its fragment found in the tested sample is an indicator of the fact that the disease is progressing or has started. What is offered is using in vitro said homeodomain-containing transcription factor or its fragment to be detected in urine as a prostate cancer biomarker.

EFFECT: high-specific and sensitive diagnostic or monitoring technique for prostate cancer progression twice exceeding the standard PSA test in effectiveness.

8 cl, 8 dwg, 4 tbl, 8 ex